Non-Hodgkin's lymphoma: case control epidemiological study in Yorkshire.

Abstract:

:This paper reports the results of a case control study of non-Hodgkin's lymphoma in the Yorkshire Health Region. In all, 437 cases and 724 controls were interviewed. Risk factors associated with past skin conditions, family history of cancer and infectious mononucleosis, aspects of social life and contact with wood dust and epoxy glues all emerge. A comparison of high and low grade morphological forms of disease reveal contrasting risks and suggest separate aetiologies for these conditions.

journal_name

Leuk Res

journal_title

Leukemia research

authors

Cartwright RA,McKinney PA,O'Brien C,Richards ID,Roberts B,Lauder I,Darwin CM,Bernard SM,Bird CC

doi

10.1016/s0145-2126(98)80012-x

subject

Has Abstract

pub_date

1988-01-01 00:00:00

pages

81-8

issue

1

eissn

0145-2126

issn

1873-5835

journal_volume

12

pub_type

杂志文章
  • Fusion oncogenic tyrosine kinases alter DNA damage and repair after genotoxic treatment: role in drug resistance?

    abstract::Fusion tyrosine kinases (FTKs) such as BCR/ABL, TEL/ABL, TEL/JAK2, TEL/PDGF beta R and NPM/ALK arise from reciprocal chromosomal translocations and cause acute and chronic myelogenous leukemias and non-Hodgkin's lymphoma. Murine hematopoietic growth factor dependent BaF3 cells and cells transformed by FTK (BaF3-FTK) w...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/s0145-2126(02)00163-7

    authors: Hoser G,Majsterek I,Romana DL,Slupianek A,Blasiak J,Skorski T

    更新日期:2003-03-01 00:00:00

  • PD-1/PD-L1 expression in extra-medullary lesions of multiple myeloma.

    abstract::Multiple myeloma patients may develop extraosseous involvement in the course of the disease making prognosis very poor and new drugs clearly needed. The PD-1/PD-L1 axis has emerged as a master immune checkpoint in antitumor responses and recent studies investigated the role of PD-L1 in multiple myeloma cells; no data ...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2016.09.008

    authors: Crescenzi A,Annibali O,Bianchi A,Pagano A,Donati M,Grifoni A,Avvisati G

    更新日期:2016-10-01 00:00:00

  • Candidate gene mutation analysis in idiopathic acquired sideroblastic anemia (refractory anemia with ringed sideroblasts).

    abstract:BACKGROUND:For most cases of idiopathic acquired sideroblastic anemia (IASA), the molecular pathogenesis is unknown, despite the consistent morphological signature of abundant pathological ringed sideroblasts with their characteristic iron-engorged mitochondria. Moderately elevated free erythrocyte protoporphyrin (FEP)...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2006.06.005

    authors: Steensma DP,Hecksel KA,Porcher JC,Lasho TL

    更新日期:2007-05-01 00:00:00

  • CD14 mediated endogenous TNF-alpha release in HL60 AML cells: a potential model for CD14 mediated endogenous cytokine release in the treatment of AML.

    abstract::In previous studies, HL60 AML cells treated with tumor necrosis factor-alpha (TNF), interferon-gamma (IFN), and lipopolysaccharides (LPS) displayed decreased growth and viability, enhanced monocytic pathway differentiation and endogenous TNF release. Endogenous TNF release by LPS/TNF/IFN treated HL60 cells was postula...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/0145-2126(94)90004-3

    authors: Treon SP,Anand B,Ulevitch R,Broitman SA

    更新日期:1994-01-01 00:00:00

  • Allogeneic marrow transplantation for acute leukemia in relapse.

    abstract::The results of allogeneic marrow transplantation in 75 patients with acute lymphoblastic leukemia and 63 patients with acute non-lymphoblastic leukemia in relapse are reviewed. The effects of various chemotherapeutic regimens added to the basic regimen of cyclophosphamide (Cy) 60 mg/kg given on each of two successive ...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/0145-2126(82)90101-1

    authors: Badger C,Buckner CD,Thomas ED,Clift RA,Sanders JE,Stewart PS,Storb R,Sullivan KM,Shulman H,Flournoy N

    更新日期:1982-01-01 00:00:00

  • The venom of the spider Macrothele raveni induces apoptosis in the myelogenous leukemia K562 cell line.

    abstract::Spider venoms are a rich source of bioactive compounds with therapeutic potential. In traditional Chinese medicine, spiders and spider venoms have been used in the treatment of various ailments. In the present study, the venom of the spider Macrothele raveni potently suppressed cell growth in the myelogenous leukemia ...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2012.02.025

    authors: Liu Z,Zhao Y,Li J,Xu S,Liu C,Zhu Y,Liang S

    更新日期:2012-08-01 00:00:00

  • The combined differentiating effect of retinoic acid and vincristine on acute promyelocytic leukemia.

    abstract::We have previously shown that HL-60 cells exposed to all-trans retinoic acid (ATRA) after treatment with a non-cytotoxic concentration of vincristine (VCR) result in granulocytic maturation and differentiation, suggesting that VCR might exhibit a synergistic action with ATRA in the treatment of acute promyelocytic leu...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/s0145-2126(96)00090-2

    authors: Leung M,Wong K

    更新日期:1997-01-01 00:00:00

  • Decreased microRNA-30a levels are associated with enhanced ABL1 and BCR-ABL1 expression in chronic myeloid leukemia.

    abstract::Chronic myeloid leukemia (CML) is associated with overexpression of BCR-ABL1, a nonreceptor tyrosine kinase critical for malignant transformation. We investigated whether non-coding microRNAs (miRNAs) targeting BCR-ABL1 mRNA contribute to the pathogenesis of CML. Indeed, miR-30a targeted BCR-ABL1 and was underexpresse...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2012.12.003

    authors: Liu Y,Song Y,Ma W,Zheng W,Yin H

    更新日期:2013-03-01 00:00:00

  • Malignant hematopoietic cell lines: in vitro models for the study of Waldenström's macroglobulinemia.

    abstract::Model cell lines are essential tools for investigating the biology and therapeutics of cancer. Approximately 1500 human hematopoietic neoplastic cell lines have been described, covering most major disease entities. Waldenström's macroglobulinemia (WM) is a rare incurable hematological neoplasm from which only three ce...

    journal_title:Leukemia research

    pub_type: 杂志文章,评审

    doi:10.1016/j.leukres.2008.04.016

    authors: Drexler HG,MacLeod RA

    更新日期:2008-11-01 00:00:00

  • Human interleukin 4 regulates the phenotype of lymphocytes generated during mixed lymphocyte culture and inhibits the IL-2-induced development of LAK function in normal and leukaemic cells.

    abstract::This study examined the immunoregulatory role of recombinant interleukin 4 (IL-4), also known as B-cell stimulating factor 1, on the generation of cytotoxic effector cells from normal and leukaemic human blood mononuclear cells. When tested on cells from normal individuals, the addition of IL-4 to mixed lymphocyte cul...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/0145-2126(89)90066-0

    authors: Jin BQ,Lopez AF,Gillis S,Juttner CA,Vadas MA,Burns GF

    更新日期:1989-01-01 00:00:00

  • Administration of ATRA to newly diagnosed patients with acute promyelocytic leukemia is delayed contributing to early hemorrhagic death.

    abstract::We hypothesized that the high early death rate (EDR) due to bleeding in acute promyelocytic leukemia (APL) is in part attributable to delays in all- trans retinoic acid (ATRA). We conducted a retrospective analysis of the timing of ATRA administration. 204 consecutive patients with newly diagnosed APL between 1992 and...

    journal_title:Leukemia research

    pub_type: 杂志文章,多中心研究

    doi:10.1016/j.leukres.2013.05.007

    authors: Altman JK,Rademaker A,Cull E,Weitner BB,Ofran Y,Rosenblat TL,Haidau A,Park JH,Ram SL,Orsini JM Jr,Sandhu S,Catchatourian R,Trifilio SM,Adel NG,Frankfurt O,Stein EM,Mallios G,Deblasio T,Jurcic JG,Nimer S,Peterson L

    更新日期:2013-09-01 00:00:00

  • Induction of cytidine deaminase in HL-60 myeloid leukemic cells by 5-aza-2'-deoxycytidine.

    abstract::5-Aza-2'-deoxycytidine (5-AZA-CdR), a potent inhibitor of DNA methylation and an active antileukemic agent, produced an induction of cytidine deaminase activity in human HL-60 myeloid leukemic cells. This increase in enzyme activity correlated with the induction of differentiation of the HL-60 leukemic cells as shown ...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/0145-2126(90)90067-j

    authors: Momparler RL,Laliberté J

    更新日期:1990-01-01 00:00:00

  • Protection from apoptotic cell death by interleukin-4 is increased in previously treated chronic lymphocytic leukemia patients.

    abstract::Chronic lymphocytic leukemia (CLL) cells were cultured in a medium supplemented with 0.01-1 ng/ml interleukin-4 (IL-4) for 18 h, fixed and analyzed on a flow cytometer. The percentage of apoptotic (AP) cells with hypodiploid DNA content was determined from DNA histograms. IL-4 at 0.01 ng/ml protected from spontaneous ...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/s0145-2126(96)00053-7

    authors: Frankfurt OS,Byrnes JJ,Villa L

    更新日期:1997-01-01 00:00:00

  • Increased C-kit intensity is a poor prognostic factor for progression-free and overall survival in patients with newly diagnosed AML.

    abstract::C-kit, a tyrosine kinase receptor, is expressed on most myeloid blasts and is thought to be important in the pathogenesis of AML. Activation of the c-kit receptor leads to phosphorylation and activation of downstream signaling proteins, which are important for cell survival and proliferation. Here, we discuss the prog...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2007.08.019

    authors: Advani AS,Rodriguez C,Jin T,Jawde RA,Saber W,Baz R,Kalaycio M,Sobecks R,Sekeres M,Tripp B,Hsi E

    更新日期:2008-06-01 00:00:00

  • Preclinical and clinical results with pomalidomide in the treatment of relapsed/refractory multiple myeloma.

    abstract::Despite the evolution of effective frontline treatment strategies, many patients with myeloma inevitably relapse. Treatment can be complicated by the interplay of disease-, treatment-, and patient-related factors. Unfortunately, many patients eventually develop disease that is refractory to lenalidomide and bortezomib...

    journal_title:Leukemia research

    pub_type: 杂志文章,评审

    doi:10.1016/j.leukres.2014.02.008

    authors: Mark TM,Coleman M,Niesvizky R

    更新日期:2014-05-01 00:00:00

  • Negative regulatory elements are present in the human LMO2 oncogene and may contribute to its expression in leukemia.

    abstract::Ectopic expression of LMO2 occurs in approximately 45% of T-lineage acute lymphoblastic leukemias (T-ALL), sometimes in association with chromosomal translocations. Recently, a lymphoproliferative disorder developed in two participants in a gene therapy trial due to LMO2 activation via integration of the retroviral ve...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2004.05.013

    authors: Hammond SM,Crable SC,Anderson KP

    更新日期:2005-01-01 00:00:00

  • Enhanced delivery of synthetic oligonucleotides to human leukaemic cells by liposomes and immunoliposomes.

    abstract::The ability of pH-sensitive liposomes and immunoliposomes to deliver synthetic antisense oligonucleotides (oligos) into human myeloid and lymphoid leukaemia cells was examined. The cellular uptake of an 18mer anti-myb oligonucleotide encapsulated in liposomes was from three- to five-fold higher than that of 32P-oligos...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/s0145-2126(96)00062-8

    authors: Ma DD,Wei AQ

    更新日期:1996-11-01 00:00:00

  • Over-expression of Flt3 induces NF-kappaB pathway and increases the expression of IL-6.

    abstract::Activating mutations or over-expression of the Flt3 is prevalent in acute myeloblastic leukemia (AML), associated with activation of Ras/MAP kinase and other signaling pathways. In this study, we addressed the role of Flt3 in the activation of nuclear factor-kappa B (NF-kappaB), which is a target molecule of these kin...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2005.01.008

    authors: Takahashi S,Harigae H,Ishii KK,Inomata M,Fujiwara T,Yokoyama H,Ishizawa K,Kameoka J,Licht JD,Sasaki T,Kaku M

    更新日期:2005-08-01 00:00:00

  • The expression of PRAME in chronic lymphoproliferative disorders.

    abstract::The PRAME gene encodes an antigen recognized by autologous T lymphocytes and is expressed in trophoblasts, testis and frequently in human solid cancers and acute leukemias, making it a candidate for immunotherapy and for detecting MRD. We demonstrate expression of PRAME by RT-PCR in the peripheral blood or bone marrow...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/s0145-2126(02)00217-5

    authors: Proto-Siqueira R,Falcão RP,de Souza CA,Ismael SJ,Zago MA

    更新日期:2003-05-01 00:00:00

  • High incidence of chronic lymphocytic leukemia (CLL) diagnosed by immunophenotyping: a population-based Canadian cohort.

    abstract::Incidence and outcomes of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) are not well established at the population level, especially since the widespread use of immunophenotyping. We studied the epidemiology of CLL in Manitoba (Canada) by combining data from a centralized flow cytometry facility and th...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2009.06.013

    authors: Seftel MD,Demers AA,Banerji V,Gibson SB,Morales C,Musto G,Pitz MW,Johnston JB

    更新日期:2009-11-01 00:00:00

  • High-dose cytarabine-based consolidation shows superior results for older AML patients with intermediate risk cytogenetics in first complete remission.

    abstract::We evaluated outcomes in two consecutive groups of AML patients age>60 years in CR after 7+3 induction therapy. Group 1 received consolidation with cytarabine 1.5g/m(2) q12h×6+daunorubicin for two cycles, while group 2 received consolidation with 7+3 followed by mitoxantrone+etoposide. For patients with intermediate-r...

    journal_title:Leukemia research

    pub_type: 临床试验,杂志文章

    doi:10.1016/j.leukres.2013.01.001

    authors: Hassanein M,Atenafu EG,Schuh AC,Yee KW,Minden MD,Schimmer AD,Gupta V,Brandwein JM

    更新日期:2013-05-01 00:00:00

  • Neurotoxicity of stem cell mobilization chemotherapy with vinorelbine in myeloma patients after bortezomib treatment.

    abstract::Vinorelbine chemotherapy with G-CSF stimulation is the standard mobilization regimen in Switzerland for multiple myeloma patients. However, with the increasing use of bortezomib during induction treatment, adding the neurotoxic compound vinorelbine for mobilization may aggravate bortezomib-induced polyneuropathy. In t...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2015.03.015

    authors: Keller S,Seipel K,Novak U,Mueller BU,Taleghani BM,Leibundgut K,Pabst T

    更新日期:2015-07-01 00:00:00

  • Enhanced topoisomerase II-induced DNA breaks and free radical production by a new anthracycline with potent antileukemic activity.

    abstract::In a previous study we reported that a new anthracycline derivative (moflomycin) exhibited a higher antileukemic activity compared to other anthracyclines, such as daunorubicin and doxorubicin. To explain the superior antileukemic effect of moflomycin and to disclose a possible structure-activity relationship, we inve...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/0145-2126(95)00155-7

    authors: Andrivon W,Saucier JM,Auclair C,Monneret C,Florent JC,Guillosson JJ,Nafziger J

    更新日期:1996-02-01 00:00:00

  • Characterization of the AKR thymic microenvironment and its influence on thymocyte differentiation and lymphoma development.

    abstract::The thymic stroma has long been implicated in AKR thymic leukaemia. In this study an extensive panel of monoclonal antibodies was used to investigate changes in the AKR thymic microenvironment, in parallel with thymocyte differentiation of normal (2 month), preleukaemic (5-7 month) and leukaemic (> 7 month) mice. We f...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/0145-2126(95)00102-6

    authors: Davey GM,Tucek-Szabo CL,Boyd RL

    更新日期:1996-10-01 00:00:00

  • Establishment and characterization of the tumors of chronic lymphocytic leukemia cell line in nude and SCID mice.

    abstract::A new cell line, designated MO1043, was established from the peripheral blood (PB) of a patient with B-cell chronic lymphocytic leukemia (CLL). Both the PB leukemia cells and MO1043 were found to have an abnormal cytogenetic marker of trisomy 12, the most common cytogenetic abnormality in CLL. In addition, both the PB...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/0145-2126(93)90154-d

    authors: Kawata A,Han T,Dadey B,Weier HU,Okazaki M,Yokota S,Fukiage T,Xiao H,Block AM,Barcos M

    更新日期:1993-10-01 00:00:00

  • Clinico-pathological characteristics of myeloid sarcoma at diagnosis and during follow-up: report of 12 cases from a single institution.

    abstract::The aim of this study was to describe the presenting features, the frequency and outcome of myeloid sarcoma (MS) diagnosed in our Institution from January 1995 to December 2000. Twelve MS were seen and the frequency account for only 2% of all acute myeloid leukemia (AML) patients observed in our department in the same...

    journal_title:Leukemia research

    pub_type: 杂志文章,评审

    doi:10.1016/j.leukres.2004.01.022

    authors: Breccia M,Mandelli F,Petti MC,D'Andrea M,Pescarmona E,Pileri SA,Carmosino I,Russo E,De Fabritiis P,Alimena G

    更新日期:2004-11-01 00:00:00

  • Dasatinib first-line: Multicentric Italian experience outside clinical trials.

    abstract::Dasatinib was approved for the treatment of chronic phase (CP) chronic myeloid leukemia (CML) patients in first line therapy based on the demonstration of efficacy and safety reported in patients enrolled in clinical trials. We describe a multicentric Italian "real-life" experience of dasatinib used as frontline treat...

    journal_title:Leukemia research

    pub_type: 杂志文章,多中心研究

    doi:10.1016/j.leukres.2015.11.008

    authors: Breccia M,Stagno F,Luciano L,Abruzzese E,Annunziata M,D'Adda M,Maggi A,Sgherza N,Russo-Rossi A,Pregno P,Castagnetti F,Iurlo A,Latagliata R,Cedrone M,Di Renzo N,Sorà F,Rege-Cambrin G,La Nasa G,Scortechini AR,Greco G

    更新日期:2016-01-01 00:00:00

  • Inositol lipid metabolism accompanies erythroid differentiation of K562 human leukemic cells.

    abstract::The role of hemin induction of K562 in inositol phospholipid metabolism has not been previously studied. K562 cells were induced to synthesize hemoglobin upon addition of bovine hemin to the culture media. The phospholipid content of K562 was determined before and after the addition of hemin. The results of this study...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/0145-2126(91)90055-x

    authors: Klette KL,Wanda PE

    更新日期:1991-01-01 00:00:00

  • The reproducibility of acute lymphoblastic leukemia phenotype determinations: evaluation of monoclonal antibody and conventional hematopoietic markers.

    abstract::Peripheral blood and/or bone marrow lymphoblasts from 25 patients with acute lymphoblastic leukemia (ALL) were tested with a panel of monoclonal antibodies (MoAbs) and conventional hematopoietic markers by three different laboratories. The results were analysed to evaluate the reproducibility of ALL phenotype determin...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/0145-2126(86)90083-4

    authors: Sobol RE,Mick R,LeBien TW,Ozer H,Minowada J,Anderson K,Ellison RR,Cuttner J,Morrison A,Richards F 2nd

    更新日期:1986-01-01 00:00:00

  • The clinical characteristics and prognosis of IGH deletion in multiple myeloma.

    abstract:OBJECTIVE:To analyze the frequency, clinical characteristics, and prognosis of IGH deletion in multiple myeloma (MM). METHODS:A total of 310 consecutive patients with multiple myeloma were analyzed. Among them 251 patients were newly diagnosed and 59 patients were previously treated, fluorescence in situ hybridization...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2015.02.010

    authors: He H,Fu W,Jiang H,Du J,Zhou L,Zhang C,Xi H,Li R,Hou J

    更新日期:2015-05-01 00:00:00